Stockreport

Five Prime Announces Cabiralizumab Phase 1a/1b Data Abstract Selected for Late Breaking Oral Presentation at the Society for Immunotherapy of Cancer (SITC) 32nd Annual Meeting

FIVE PRIME THERAPEUTICS  (FPRX) 
Last five prime therapeutics earnings: 2/27 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.fiveprime.com/investor-relations
PDF SOUTH SAN FRANCISCO, Calif., Oct. 11, 2017 (GLOBE NEWSWIRE) -- Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discoveri [Read more]